Tariff Plans on Generic Drugs: The Trump administration is not currently planning to impose tariffs on generic drug imports, as confirmed by White House officials, although this decision could change in the future.
Concerns Over Tariffs: Officials have expressed concerns that imposing tariffs on generic drugs could lead to price increases and shortages, given that 90% of prescriptions in the U.S. are for generics, and production costs are significantly lower in countries like India.
Focus on Domestic Manufacturing: The administration is exploring ways to enhance U.S. manufacturing of generic drugs, potentially through government assistance such as federal grants or loans, to reduce reliance on foreign supply chains.
Negotiation Delays: President Trump has delayed the imposition of tariffs on name-brand drugs to allow for further negotiations with drugmakers, indicating a strategic approach to the pharmaceutical sector.
Wall Street analysts forecast XPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XPH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast XPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XPH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 57.510
Low
Averages
High
Current: 57.510
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
